Vontobel Holding Ltd. Acquires 2,047 Shares of Stryker Corporation $SYK

Vontobel Holding Ltd. grew its holdings in Stryker Corporation (NYSE:SYK) by 2.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 100,746 shares of the medical technology company’s stock after acquiring an additional 2,047 shares during the period. Vontobel Holding Ltd.’s holdings in Stryker were worth $31,719,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in the business. VanderPol Investments L.L.C. grew its position in shares of Stryker by 1.4% during the fourth quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock worth $732,000 after purchasing an additional 28 shares in the last quarter. KCM Investment Advisors LLC lifted its holdings in Stryker by 1.5% in the 4th quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company’s stock worth $653,000 after purchasing an additional 28 shares in the last quarter. Rossby Financial LCC lifted its holdings in Stryker by 6.6% in the 4th quarter. Rossby Financial LCC now owns 451 shares of the medical technology company’s stock worth $159,000 after purchasing an additional 28 shares in the last quarter. Tcfg Wealth Management LLC boosted its stake in Stryker by 2.7% in the 3rd quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock worth $403,000 after purchasing an additional 29 shares during the period. Finally, West Michigan Advisors LLC boosted its stake in Stryker by 0.4% in the 4th quarter. West Michigan Advisors LLC now owns 7,468 shares of the medical technology company’s stock worth $2,631,000 after purchasing an additional 30 shares during the period. Institutional investors own 77.09% of the company’s stock.

Stryker Stock Performance

NYSE SYK opened at $338.80 on Friday. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. Stryker Corporation has a 1-year low of $281.00 and a 1-year high of $396.86. The business has a 50 day simple moving average of $324.61 and a two-hundred day simple moving average of $333.57. The stock has a market capitalization of $129.95 billion, a PE ratio of 35.11, a P/E/G ratio of 2.17 and a beta of 0.76.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.49 by $0.20. The business had revenue of $6.59 billion for the quarter, compared to analysts’ expectations of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The company’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same period in the prior year, the firm earned $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, research analysts predict that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 1.0%. The ex-dividend date is Wednesday, September 30th. Stryker’s payout ratio is currently 36.48%.

Insiders Place Their Bets

In related news, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the sale, the director owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. This represents a 13.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the transaction, the vice president owned 10,582 shares of the company’s stock, valued at $3,247,298.34. This trade represents a 30.04% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.60% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on SYK. Robert W. Baird set a $385.00 price objective on shares of Stryker in a research report on Friday, May 1st. Wolfe Research lowered shares of Stryker from an “outperform” rating to a “peer perform” rating in a research report on Thursday. Wells Fargo & Company cut their target price on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating for the company in a research note on Friday, May 1st. Wall Street Zen upgraded shares of Stryker from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Finally, Citizens Jmp decreased their price target on shares of Stryker from $440.00 to $400.00 and set a “market outperform” rating on the stock in a research note on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $386.28.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.